70 Avenue Tony Garnier
Lyon 69007
France
33 4 28 29 14 00
https://www.maatpharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 52
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Herve Affagard | CEO, Co-Founder & Director | 271,2k | S.O. | 1975 |
Dr. Joel Dore Ph.D. | Co-Founder & Member of Scientific Advisory Board | S.O. | S.O. | S.O. |
Mr. Pierre Rimbaud | Co-Founder | S.O. | S.O. | S.O. |
Ms. Sian Crouzet | Chief Financial Officer | S.O. | S.O. | S.O. |
Ms. Carole Schwintner | Chief Technology Officer | S.O. | S.O. | S.O. |
Dr. Nathalie Corvaia Ph.D. | Chief Scientific Officer | S.O. | S.O. | S.O. |
Guilhaume Debroas Ph.D. | Head of Investor Relations | S.O. | S.O. | S.O. |
Dr. Emilie Plantamura | Head of Clinical Development | S.O. | S.O. | S.O. |
Mr. Jonathan Chriqui Pharm.D. | Chief Business Officer | S.O. | S.O. | S.O. |
Dr. Gianfranco Pittari M.D., Ph.D. | Chief Medical Officer | S.O. | S.O. | S.O. |
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
L’ISS Governance QualityScore de MaaT Pharma SA en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..